KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Receivables (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Receivables for 8 consecutive years, with $51.9 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 20.53% to $51.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.9 million through Dec 2025, up 20.53% year-over-year, with the annual reading at $51.9 million for FY2025, 20.53% up from the prior year.
  • Receivables hit $51.9 million in Q4 2025 for Adaptive Biotechnologies, up from $46.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $51.9 million in Q4 2025 to a low of $16.5 million in Q2 2021.
  • Historically, Receivables has averaged $34.2 million across 5 years, with a median of $34.6 million in 2023.
  • Biggest five-year swings in Receivables: soared 117.22% in 2022 and later decreased 4.62% in 2023.
  • Year by year, Receivables stood at $18.8 million in 2021, then skyrocketed by 117.22% to $40.9 million in 2022, then fell by 4.62% to $39.0 million in 2023, then increased by 10.42% to $43.0 million in 2024, then grew by 20.53% to $51.9 million in 2025.
  • Business Quant data shows Receivables for ADPT at $51.9 million in Q4 2025, $46.3 million in Q3 2025, and $45.6 million in Q2 2025.